Allotex is an Italian and American startup founded in 2014 that has developed TransForm™, a biocompatible corneal inlay to solve presbyopia. Once implanted in the non-dominant eye, it allows to immediately get rid of reading spectacles without impact on distant vision. Procedure is below 10min and well established. As of today, about 30% of population in its 40-60y has presbyopia
Location: United States, Massachusetts, Boston
Employees: 11-50
Investors 2
| Date | Name | Website |
| - | Panakes Pa... | panakes.it |
| - | KCK Medtec... | kckmedtech... |
Mentions in press and media 4
| Date | Title | Description |
| 03.06.2025 | Allotex Appoints Dirk Muehlhoff to its Board of Directors | Dirk Muehlhoff, MBA, Dipl Phys Seasoned ophthalmic industry leader joins Allotex Board to strengthen strategic positioning and support global scale-up of its presbyopia correction platform. The company’s commitment to innovation through bio... |
| 04.12.2023 | Allotex Receives Investment from Junson Capital | Allotex Inc. and SpA, a Boston, MA- and Milan, Italy-based biologics and device company specializing in vision correction therapies, received an investment from Junson Capital. Junson Capital has joined the existing investors including KCK ... |
| 01.12.2023 | Allotex Announces New Investor and Expansion of Production Facilities | BOSTON and MILAN, Dec. 1, 2023 /PRNewswire/ -- Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, is pleased to announce that Junson Capital has joined its investor syndicate. This addi... |
| - | Allotex | “Allograft Inlays & Onlays” |